Biggest loser was my SIPP holding of TLOU:Tlou Energy which fell by 12%, which was a mystery given they secured financing for the transmission lines, which I thought would generate a re-rate upwards. There were misleading bulletin board posts about death spiral loans which could have spooked some people, but surely not enough would be fooled to cause such a big drop? I suspect these may stagnate until the hydrogen production facility is build early next year, as that will start to generate some income.
SBTX:SkinBioTherapeutics was my next biggest lose, which is depressing given
I only bought them this week! I have said for some time that I will buy back
in when they go under 50p, and that happened the day before results day. I
sold 5,000 JLP:Jubilee Metals shares and added £255 so I could buy 2,116
shares at 47.245p costing £1,011.65. On results day they dropped below 40p
and ended the week at 45p bid price, so most of the deficit is spread.
When the price collapsed following results I sold my CAML:Central Asia
Metals holding and bought 3,180 SBTX shares at 45.22p costing £1,449.95.
Those are only 2% down so a lot less distressing. I'll buy back into
CAML:Central Asia Metals with my next transfer in February, in time for
dividend day in April.
ASY:Andrews Sykes Group has been pretty static since I bought them, but
dropped 6% this week for no reason other than the market being rubbish.
CMCL:Caledonia Mining and HUM:Hummingbird Resources also dropped 6% as the
price of gold dipped below $1,800, and PAF:Pan African Resources dropped
5% but went ex-dividend so has a better excuse. Blackrock World Gold Fund
also dropped 5% to go into loss.
OPTI:Optibiotix dropped 2p despite news of a new deal for LeanBiome which
will result in £1m new revenue in 2022. So a 25%+ increase in revenue
causes a share price drop? Well I never!
Share of the Week is one of the few that gained anything this week.
JLP:Jubilee Metals climbed 24% of my purchase price following superb
results. I feel a tad guilty that I rewarded them by selling some more.
Thankfully above the injection line
Devastating
Here's the ISA and shares portfolio after week 18 of year 7.
Profit from sales increased by £568 thanks to selling 5,000 JLP:Jubilee Metals at 15.91p to make £568.35 (250%) profit. Potential profits only dropped by £359 as JLP went up after my sale. I also added another £55 cash as there's an open offer for IES:Invinity Energy coming up and it's a good chance to reduce my average price so I'll take part, as there's hope things could start happening with some bigger orders coming in.
| Weekly Change | |||
| Cash | £87.05 |
+£76.90 | |
| Portfolio cost | £72,145.21 | +£796.45 | |
| Portfolio sell value (bid price-commission) | £47,184.69 | (-34.6%) | -£2,311.81 |
| Potential profits | £2,515.29 | -£359.80 | |
| Yr 7 Dividends | £22.16 | +£0 | |
| Yr 7 Profit from sales | £3,664.29 | +£568.35 | |
| Yr 7 projected avg monthly profit | £889.20 | (24.1%) | +£97.26 |
| Total Dividends | £1,365.31 | +£0 | |
| Total Profit from sales | £27,788.23 | +£568.35 | |
| Average monthly cash profit |
£379.22 |
(10.3%) | +£6.57 |
|
(Sold stocks profit + Dividends - Fees / Months) |
|||
| Compound performance | 65% | +1% |
Profit from sales increased by £568 thanks to selling 5,000 JLP:Jubilee Metals at 15.91p to make £568.35 (250%) profit. Potential profits only dropped by £359 as JLP went up after my sale. I also added another £55 cash as there's an open offer for IES:Invinity Energy coming up and it's a good chance to reduce my average price so I'll take part, as there's hope things could start happening with some bigger orders coming in.
Long term performance improved by £6 a month and is still healthy at
10.3%, with year 7 projected profit even better at 24%, but that won't
last as I don't have much more JLP left to sell. We won't mention the
£2,311 drop in portfolio value...
Worryingly close to the injection line
On the cusp of having to change the lower limit of the chart.
Worryingly close to the injection line
On the cusp of having to change the lower limit of the chart.
The SIPP looks like this after week 314 overall and week 2 of year 7.
Another huge drop in portfolio value, and the sale of CAML:Central Asia Metals only increased the long term performance by 0.1% so we're still below 10% target. The CAML sale was 600 shares at 237.89p to make £267.70 (24%) profit. I hate being out of these and want to buy back asap, but I really wanted to get into SBTX:SkinBioTherapeutics before they announce any of the Croda deals, as I think they are imminent.
| Weekly Change | ||||
| Cash | £260.33 | +£85.44 | ||
| Portfolio cost | £80,169.97 | +£302.25 | ||
|
Portfolio sell value (bid price - commission) |
£52,482.15 | (-34.5%) | -£2,485.56 | |
| Potential profits | £82.93 | -£263.83 | ||
| Yr 7 Dividends | £0 | +£0 | ||
| Yr 7 Interest | £0 | +£0 | ||
| Yr 7 Profit from sales | £267.69 | +£267.69 | ||
| Yr 7 projected avg monthly profit | £543.86 | (13.3%) | +£543.86 | |
| Total Dividends | £3,204.39 | +£0 | ||
| Total Interest | £0.20 | +£0 | ||
| Total Profit from sales | £23,992.32 | +£267.69 | ||
| Average monthly cash profit | £363.75 | (8.9%) | +£2.31 | |
|
(Sold stocks profit + Dividends - Fees / Months) |
||||
| Compound performance | 54% | +0% |
Another huge drop in portfolio value, and the sale of CAML:Central Asia Metals only increased the long term performance by 0.1% so we're still below 10% target. The CAML sale was 600 shares at 237.89p to make £267.70 (24%) profit. I hate being out of these and want to buy back asap, but I really wanted to get into SBTX:SkinBioTherapeutics before they announce any of the Croda deals, as I think they are imminent.
Cash increased as there was a £120 injection to cover my monthly iShares
Physical Gold fund purchase.
Also very close to the injection line
Desperate
Also very close to the injection line
Desperate
The trading account looks like this after week 280 overall and week 20 of year 6.
DDDD:4D Pharma increased slightly this week, but the rest dropped, so another £24 gone and overall down by 58% which is pretty shocking.
| Weekly Change | |||
| Cash | £259.74 | +£0 | |
| Portfolio cost | £2,374.14 | +£0 | |
| Portfolio sell value (bid price - commission) | £985.36 | (-58.5%) | -£24.55 |
| Potential profits | £0.00 | +£0 | |
| Year 6 Dividends | £0.00 | +£0 | |
| Year 6 Profit | £0.00 | +£0 | |
| Yr 6 projected avg monthly profit | £0.00 | (0%) | +£0 |
| Dividends | £60.10 | +£0 | |
| Profit from sales | £937.88 | +£0 | |
| Average monthly cash profit | £15.44 | (7.8%) | -£0.06 |
|
(Sold stocks profit + Dividends - Fees / Months) |
DDDD:4D Pharma increased slightly this week, but the rest dropped, so another £24 gone and overall down by 58% which is pretty shocking.
It just keeps getting worse.
Bang on the trend line and following it relentlessly downwards.
It feels so nice to be back invested in SBTX:SkinBioTherapeutics, as I really like the company. I was right to avoid investing at 60p, as it was over-priced, but I jumped in too quick as it dropped below 40p mid-week. However, it soon climbed back again so I don't really mind. I got in below 50p which is the important thing.
I'm expecting really good news for DDDD:4D Pharma, OPTI:Optibiotix and
SBTX:SkinBioTherapeutics before Christmas, so there is still a good chance of
a Santa rally, despite one of the worst 3 week periods in my portfolios
history.
No comments:
Post a Comment